Sibylla Biotech, Cellarity, Araris Biotech
Patronus Closes EUR27M Series A Funding
Patronus, a Berlin, Germany-based elderly care startup, raised €27m in Series A funding.
The round was led by Singular and Adjacent with participation from Burda Principal Investments, Cavalry Ventures and UVC Partners.
The company intends to use the funds to roll out the app in Q4 this year and explore opportunities to expand its product range to other stakeholders who can benefit from the digital access point for elderly users.
Led by Ben Staudt and Tim Wagner, Patronus is an elderly care startup developing digital tools to make ageing more dignified. The company currently offers digital watch software for the elderly as well as a mobile app for carers and family members.
Patronus Closes EUR27M Series A Funding - FinSMEs
Patronus, a Berlin, Germany-based elderly care startup, raised €27m in Series A funding
Araris Biotech Closes $24M Funding Round
Araris Biotech AG, a AU ZH, Switzerland-based antibody-drug conjugate company, raised $24M in funding.
The round was co-led by 4BIO Capital, and Pureos Bioventures, with participation from Wille AG, Follicular Lymphoma Innovation, VI Partners, Schroders Capital, btov Partners and Redalpine. Damir Illich, Ph.D. from Wille AG and Sophie Allauzen, Ph.D. from the Institute for Follicular Lymphoma Innovation will also be joining the Araris team as board observers.
The company intends to use the funds to support the further development and advancement of its antibody-drug conjugate candidates, created using the proprietary linker technology, as they move closer towards clinical development.
Led by CEO Philipp Spycher, Ph.D., Araris Biotech is pioneering the development of its novel antibody-drug conjugate (ADC)-linker technology to enable efficient and precise production of ADCs. Its linker platform enables the attachment of any drug payload to ‘off the shelf’ antibodies, without the need for prior antibody engineering. The resulting ADCs have shown very high activity at low doses and an improved therapeutic index compared to multiple FDA-approved ADCs. The company is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich.
Araris Biotech Closes $24M Funding Round
Araris Biotech AG, a AU ZH, Switzerland-based antibody-drug conjugate company, raised $24M in funding
Sibylla Biotech Raises €23M in Series A Funding
Sibylla Biotech, a Verona, Italy-based biotechnology company, raised €23M in Series A funding.
The round was led by V-Bio Ventures with participation from Seroba Life Sciences, 3B Future Health Fund, Claris Ventures, CDP Venture Capital, Evolution Fund, VI Partners, Indaco Venture Partners, Vertis SGR. Concurrent with the close of the fundraising, Ward Capoen from V-Bio, Bruno Montanari from Seroba, Ciro Spedaliere from Claris Ventures, and Marianne Bjordal from 3B Future Health Fund will join Sibylla’s Board of Directors.
The company intends to use the capital for the further development of its Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT) approach, which provides access to a new class of pharmacological targets that transiently appear during the process of protein folding, and to advance its proprietary pipeline programs through preclinical evaluation. The proceeds will allow the company to build out its pipeline of therapeutics by exploiting the protein folding simulation platform, as well as to further expand the potentiality of its technology.
Led by CEO Lidia Pieri, Sibylla Biotech designs Folding Interfering Degraders (FIDs), classical small molecules that target specific proteins, including proteins that lack druggable pockets in their native state, that can address a range of therapeutic areas. The company’s lead candidate degrades Cyclin D1, a protein that is amplified and overexpressed in a range of cancers and which is currently considered an undruggable target.
Sibylla Biotech Raises €23M in Series A Funding
Sibylla Biotech, a Verona, Italy-based biotechnology company, raised €23M in Series A funding
Nested Therapeutics Emerges From Stealth With $125M To Fight Cancer
Nested Therapeutics, an early-stage oncology startup, launched on Thursday armed with $125 million in financing to advance its suite of technology for cancer treatment.
The Massachusetts-based company raised a $90 million Series A round led by Goldman Sachs Asset Management with additional funding from Foresite Capital, Cowen Healthcare Investments and Avidity Partners earlier this week.
Nested Therapeutics developed a drug discovery platform that allows the company to look for alternative ways for drugs to find cancer cells and kill them.
https://news.crunchbase.com/health-wellness-biotech/nested-cancer-treatment/Cellarity Closes $121M Series C Financing
Cellarity, a Somerville, MA-based life sciences company, raised $121M in Series C funding.
The round, which brought total funding raised to date to $274m, was led by Flagship Pioneering with participation from Kyowa Kirin and Hanwha Impact Partners.
The company intends to use the funds to grow its talent base, strengthen its platform, and advance its pipeline toward the clinic.
Led by CEO Fabrice Chouraqui, Cellarity has developed capabilities combining high-resolution data, single-cell technologies, and machine learning to investigate complex disease biology and purposefully design breakthrough medicines.
To create medicines, the company looks beyond individual molecular targets and instead focuses on the whole cell. It uses single-cell technologies to identify cellular drivers during the transition from health to disease and applies proprietary deep learning models to create drugs that reverse disease at the level of the cell. Cellarity has developed capabilities to link biology and chemistry with high dimensional, transcriptomic data to design medicines against the cellular signature of the disease. The platform provides critical insights into cellular dysfunction and reveals new biology through which we can address a range of diseases, including those which presently lack a known druggable target.
Cellarity Closes $121M Series C Financing
Cellarity, a Somerville, MA-based life sciences company, raised $121M in Series C funding
InVita Healthcare Technologies Buys BloodHub
InVita Healthcare Technologies, a Baltimore, MD-based provider of software solutions to healthcare, acquired BloodHub, a Phoenix, AZ-based provider of blood and biologics supply chain automation solutions.
The amount of the deal was not disclosed.
With the acquisition, InVita Healthcare Technologies will combine entity’s solution portfolio to support every process critical to blood center operations from the moment donors are recruited until blood products are ordered, collected, manufactured, tested, and delivered to hospitals. BloodHub is joining InVita’s Blood Management Division to form a complete provider of connected software solutions to blood centers in North America.
Led by CEO Michael Pandelakis, BloodHub is a company focused on delivering web enabled blood management applications. Over 60% of US’ blood supply orders are processed through BloodHub’s flagship order-to-cash cycle automation solution. Its newest offering, BloodRelay, is a 510(k)-cleared system that automates IRL (Immunohematology Reference Lab) workflows including patient and sample management, testing, and reporting.
InVita Healthcare Technologies Buys BloodHub - FinSMEs
InVita Healthcare Technologies, a Baltimore, MD-based provider of software solutions to healthcare, acquired BloodHub, a Phoenix, AZ-based provider of blood and biologics supply chain automation solutions
Knowtion Health Acquires Amplus
Knowtion Health (fka RSource Healthcare), a Boca Raton, FL-based healthcare company, acquired Amplus, a Torrance, CA-based provider of healthcare revenue cycle A/R resolution and technology service.
The amount of the deal was not disclosed.
With the acquisition, Knowtion will accelerate its plan to expand low balance recovery technologies to reach its scalability goals. The two companies will leverage and combine their revenue cycle management capabilities to accelerate growth in the healthcare sector.
Led by CEO Satchel Kiefer, Amplus uses machine learning and automation to support accounts receivable (A/R) for health system revenue cycles.
Led by CEO Jayson Yardley, Knowtion Health helps the health system revenue cycle resolve denied and complex claims, recover low balance accounts, and defend against payer audits, tipping the balance of power back to the provider. The company is positioned to deliver claims denial management solutions to hospitals and health systems of all sizes and types.
Knowtion Health Acquires Amplus
Knowtion Health (fka RSource Healthcare), a Boca Raton, FL-based healthcare company, acquired Amplus, a Torrance, CA-based provider of healthcare revenue cycle A/R resolution and technology service
Andera Partners Raises Life Sciences Fund, at €456M
Andera Life Sciences, a Paris, France-based business unit of the asset management company Andera Partners specialising in innovative therapeutics and medical technologies , closed its BioDiscovery 6 fund, at €456m.
Existing institutional investors include funds of funds, insurance companies, pension funds, family offices, private investors and pharmaceutical companies.
The new fund will enable the management team to pursue its investment strategy focused on building a balanced portfolio of innovative companies developing therapeutics and medical technologies, at all stages of their development, in Europe and the United States. To date, BioDiscovery 6 has made six investments in Evommune, Amolyt, TargED, Tubulis, Mineralys and Imcheck.
The Andera Life Sciences partners include Sofia Ioannidou, Olivier Litzka, Gilles Nobécourt, Jan Van den Bossche, Raphaël Wisniewski.
Since its inception, the BioDiscovery fund family has raised over 1.1 billion euros and the team has invested in over eighty European and North American therapeutics and medical technology companies, thereby becoming a benchmark in investment dedicated to life sciences.
Andera Partners Raises Life Sciences Fund, at €456M
Andera Life Sciences, a Paris, France-based business unit of the asset management company Andera Partners specialising in innovative therapeutics and medical technologies , closed its BioDiscovery 6 fund, at €456m
Red Tree Venture Capital Closes Inaugural Fund, at $272M
Red Tree Venture Capital, a West Coast-centric, early stage-biased life science venture capital firm, announced a $272m final close of its inaugural fund, Red Tree Venture Capital Fund I.
Founded in 2020 by Heath Lukatch, Ph.D. and Jennifer Cochran, Ph.D., Red Tree is a San Francisco Bay Area-based life science venture firm focused on investing in innovation emerging from premier West Coast academic and research institutions. The group leverages relationships with scientific luminaries and serial entrepreneurs at the region’s leading institutions to source opportunities focused on first-in-class and/or best-in-class therapeutics addressing significant unmet needs in the areas of oncology, neurology, and immunology.
Red Tree has already committed a portion of its new fund to investments in ten companies, each of which is at the forefront of scientific innovation within its field.
